AstraZeneca to acquire Amolyt Pharma,
expanding late-stage rare disease pipeline
PUBLISHED14 March 2024
Amolyt development portfolio includes Phase III asset with potential to address
significant unmet need in patients with chronic hypoparathyroidism
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond
complement inhibition, building on company’s success in bone metabolism and
opportunity in rare endocrinology
https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-amolyt.html
AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.86 |
Change
0.640(3.17%) |
Mkt cap ! $2.666B | |||
| Open | High | Low | Value | Volume |
| $20.45 | $21.10 | $20.39 | $9.299M | 447.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 671 | $20.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.86 | 262 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |